Q4 2024 Adaptive Biotechnologies Corp Earnings Call Transcript

Feb 11, 2025 / 09:30PM GMT

Transcript 8-K

Key Points

Positve

Adaptive Biotechnologies Corp (ADPT) reported a 42% increase in MRD revenue compared to 2023, driven by clinical testing and pharma.
The company obtained a new gapfill rate for its clonoSEQ test, increasing the rate by $300 per test.
Adaptive Biotechnologies Corp (ADPT) completed restructuring initiatives, resulting in a 40% reduction in cash burn from 2023.
The company ended 2024 with a robust cash position of $256 million.
Adaptive Biotechnologies Corp (ADPT) announced an exclusive strategic commercial partnership with NeoGenomics to expand its presence in the community.

Negative

Immune Medicine revenue decreased by 51% from the previous year, driven by lower Genentech amortization and reduced pharma and academic services.
Total operating spend for the quarter was $81.3 million, representing an 11% decrease from Q4 2023, but still a significant expenditure.
The company anticipates a total cash burn for 2025 between $60 million and $70 million.
Immune Medicine adjusted EBITDA loss for fiscal year 2024 increased to $26 million from $14.1 million in 2023.
The guidance for 2025 includes conservative MRD pharma services growth due to uncertainties with a new administration and broader impacts from the biopharma industry.

Operator

Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies fourth-quarter and full-year 2024 financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Karina Calzadilla, Vice President of Investor Relations and FP&A. Please go ahead.

Karina Calzadilla

Adaptive Biotechnologies Corp - Vice President - Investor Relations

Thank you, Didi, and good afternoon, everyone. I would like to welcome you to Adaptive Biotechnologies fourth-quarter and full-year '24 earnings conference call.

Earlier today, we issued a press release reporting Adaptive financial results for the fourth quarter and full year of 2024. The press release is available at www.adaptivebiotech.com. We are conducting a live webcast of this call and will be referencing to a slide presentation that has been posted to the Investors section in our corporate website

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.